Autoimmune hepatitis associated with Graves' disease

Internal Medicine

Volumn 42, Issue 4, 2003, Pages 331-335

  Cui, Binglin ^a   Abe, Masanori ^a   Hidata, Satoshi ^a   Nakanishi, Seiji ^a   Matsuura, Bunzo ^a   Michitaka, Kojiro ^a   Yamamoto, Kazuhisa ^b   Horiike, Norio ^a   Onji, Morikazu ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Matsuyama Shimin Hospital   (Japan)

Author keywords

Autoimmune hepatitis; Graves' disease; Liver histology; Propylthiouracil; Steroid therapy

Indexed keywords

AUTOANTIBODY; PREDNISOLONE; PROPYLTHIOURACIL; STEROID; THIAMAZOLE;

ADULT; ARTICLE; AUTOIMMUNE HEPATITIS; CASE REPORT; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; FEMALE; GRAVES DISEASE; HUMAN; HUMAN TISSUE; INFLAMMATORY CELL; LIVER BIOPSY; LIVER TOXICITY; LYMPHOCYTIC INFILTRATION; PLASMA CELL; PORTAL VEIN;

EID: 0037649007     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.42.331     Document Type: Article

References (19)

1. Mori T, Akamizu T, Kosugi S, et al. Recent progresss in TSH receptor studies with a new concept of "autoimmune TSH receptor disease". Endocr J 41: 1-11, 1994.
2. Krawitt EL. Autoimmune hepatictis. N Engl J Med 334: 897-903, 1996.
3. Onji M, Nonaka T, Horiike N, Moriwaki H, Muto Y, Ohta Y. Present status of autoimmune hepatitis in Japan. Gastroentol Jpn 28 (suppl 4): 134-138, 1993.
4. Inoue K, Okajima T, Tanaka E, et al. A case of Graves' disease associated with autoimmune hepatitis and mixed connected tissue disease. Endocr J 46: 173-177, 1999.
5. Levy M. Propylthiouracil hepatotoxicity. A review case presentation. Clin Pediatr 32: 25-29, 1993.
6. Kim HJ, Kim BH, Han YS, et al. The incidence of clinical characteristics of symptomatic propylthiouracil-induced hepatic injury in patients with hyperthyroidism: A single-center retrospective study. Am J Gastroenterol 96: 165-169, 2001.
7. Liaw YF, Huang MJ, Fan KD, et al. Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism. A cohort study. Ann Inten Med 118: 424-428, 1993.
8. Ichiki Y, Akahoshi M, Yamashita N, et al. Propylthiouracil-induced severe hepatitis: A case report and review of the literature. J Gastroenterol 33: 747-750, 1998.
9. Deidiker R, deMello DE. Propylthiouracil-induced fulminant hepatitis: Case report and review of the literature. Pediatr Pathol Lab Med 16: 845-852, 1996.
10. Limaye A, Ruffolo PR. Propylthiouracil-induced fatal hepatic necrosis. Am J Gastroenterol 82: 152-154, 1987.
11. Maggiore G, Larizza D, Lorini R, et al. Propylthiouracil hepatotoxity mimicking autoimmune chronic active hepatitiss. J Pediatr Gastroenterol 8: 547-548, 1988.
12. Weiss M, Hassin D, Bank H. Propylthiouracil induced hepatic damage. Arch Intern Med 140: 1184-1185, 1980.
13. Alvarez F, Berg PA, Bianchi FB, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31: 928-939, 1999.
14. Abe M, Hiasa Y, Masumoto T, et al. Clinical characteristics of autoimmune hepatitis with histological features of acute hepatitis. Hepatol Res 21: 213-219, 2001.
15. Targan SR, Landers C, Vidrich A, Czaja AJ. High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterology 108: 1159-1165, 1995.
16. Zauli D, Ghetti S, Grassi A, et al. Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. Hepatology 25: 1105-1107, 1997.
17. Sera N, Ashizawa K, Ando T, et al. Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves' disease. Thyroid 10: 595-599, 2000.
18. Toda G, Zeniya M, Watanabe F, et al. Present status of autoimmune hepatitis in Japan-correlating the characteristics with international criteria in an area with a high rate of HCV infection. J Hepatol 26: 1207-1212, 1997.
19. Biscoveanu M, Hasinski S. Abnormal results of liver function tests in patients with Graves' disease. Endocr Pract 6: 387-369, 2000.